SCHEMBL5452691

SCHEMBL5452691

Cc1c(-c2ccccc2)c(Cl)n2nc(C(C)(C)C(=O)O)nc2c1C#N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
HSD17B10 Q99714 3/20 0.40
HTT P42858 2/20 0.40
ADRA2A P08913 1/20 0.40
ADORA2A P29274 1/20 0.40
GRIA4 P48058 4/20 0.40
GRIA2 P42262 3/20 0.40
GRM5 P41594 1/20 0.40
KDM4E B2RXH2 7/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5439891 0.90 LMNA (0.39) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5441180 0.89 LMNA (0.44) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5441224 0.81 LMNA (0.48) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5450251 0.80 LMNA (0.47) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5442413 0.79 LMNA (0.39) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5447416 0.78 KDM4E (0.45) LMNAHSD17B10HTTADORA2AGRIA4
SCHEMBL5445231 0.78 KDM4E (0.43) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5440146 0.77 LMNA (0.44) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5444536 0.77 LMNA (0.47) LMNAHSD17B10HTTADRA2AADORA2A
SCHEMBL5450154 0.77 USP30 (0.34) LMNAHSD17B10HTTADORA2AGRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191395-A1 Heterocyclic compounds having antifungal activity DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
EP-1717238-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191395-A1 Heterocyclic compounds having antifungal activity ERG28, MANBA, MAN2B1 LMNA 3512/4885HSD17B10 1091/4885HTT 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.